Friday June 24, 2022 (London, UK) — Results from two trials have given researchers hope that significant progress can be made against the rise in non-alcoholic fatty liver disease (NAFLD), now the world´s fastest growing disease which affects one in four people around the globe.

The results were presented today at the International Liver Congress 2022 (ILC 2022) in London. Convened by the European Association for the Study of the Liver (EASL), the annual event returns this edition in a hybrid format with some 5000 scientists, doctors, public health officials and patient groups attending in-person at the ExCel London venue this week. Deputy Mayor of London for Business Rajesh Agrawal opened the event on Wednesday.

A first in-human trial of the drug Pemvidutide has shown that it is remarkably effective at reducing a person`s weight but that what sets its aside form weight loss drugs is that it simultaneously reduces liver fat which in excess levels can be life threatening.

In a separate randomised trial comparing two types of weight reducing diets, researchers have concluded that a low carbohydrate high fat diet is much more effective at reducing liver fat in people living with type 2 diabetes than a high carbohydrate low fat diet.

“The global burden of NAFLD is so high that we´re going to need all the prevention and treatment tools at our disposal to make any real inroads over the coming years,” said Aleksander Krag, Vice Secretary-General of EASL who is also Professor and senior consultant of Hepatology and Director of the Odense Liver Research Centre at the University of Southern Denmark and Odense University Hospital in Denmark.

“Prevention through diet is a no-brainer policy: it´s something most people can do of their own accord, and it costs governments very little. For the sake of our younger generations, we have to take the issue of good diet seriously.

“Banning advertising of junk food, for instance, would be a good start.

“But educating young people and their families is going to be the key to unlocking this looming public health disaster. People need reassuring about why a good diet is so important in the long-term which ensures they live more healthily and longer,” concluded Krag.

Liver disease is on the rise and the fastest growing cause of death in the UK compared to other major killer diseases, such as heart disease and cancer, in which the number of deaths have either remained stable or decreased. It is the biggest cause of death in people aged between 35-49 years old.

NAFLD is already the fastest growing cause of hepatocellular carcinoma (HCC), the commonest form of liver cancer in the USA, France and the UK. Non-alcohol related steatohepatitis (NASH) is the second, more serious stage of NAFLD.

If left unchecked, the annual predicted cost of NAFLD in Europe is estimated to be greater than €35 billion in direct costs to the health system, and a further €200 billion by way of wider costs to society.

Today’s official press conference highlighted four studies around NAFLD prevention and treatment selected from over 1500 abstracts being presented at ILC 2022.

The global burden of liver cancer (LC) and chronic liver diseases (CLD)

This study aimed to assess changes in the global prevalence, incidence, mortality and morbidity [disability-adjusted life-years (DALYs)] related to LC and CLD according to the etiology of CLD and 21 GBD regions of the world. Although chronic viral hepatitis B and C (CHB and CHC) and ALD have been the main drivers of burden of chronic liver disease (CLD) and liver cancer (LC), NASH has recently become more prominent. The data was obtained from the Global Burden of Disease Study 2019 (GBD 2019). Incidence, prevalence, mortality and DALYs were calculated. Annual percent change (APC) was calculated by using Joinpoint regression program, National Cancer Institute.

Zobair Younossi of the Betty and Guy Beatty Center for Integrated Research in the U.S., reported that in 2019 globally, the prevalence, incidence, mortality and DALYs from liver disease was 1.69 billion (LC 0.04% and CLD 99.96%), 2.59 million (LC 20.7% and CLD 79.3%); 1.95 million (LC 24.8% and CLD 75.3%) and 58.7 million (LC 21.3% and CLD 78.7%). Over the last decade (2009 to 2019), there was +33.7% increase in prevalence of LC and +22.7% in the prevalence of CLD. Furthermore, there was +30.0% increase in the incidence of LC and +14.8% increase in the incidence of CLD. Zobair concluded that the biggest driver of liver disease illness and mortality during the past decade (2009-2019) was NAFLD.

Abstract: The global burden of liver cancer (LC) and chronic liver diseases (CLD) is driven by non-alcoholic steatohepatitis (NASH) and alcohol liver disease (ALD) (GS008)

Session: General Session, Friday June 24, 13:40-15:40

Pemvidutide produces potent reductions in body weight and liver fat

This placebo-controlled, double-blind, first-in-human trial aimed to assess the safety and pharmacokinetics of Pemvidutide, a GLP-1/glucagon dual receptor agonist and to evaluate its effects on weight loss and liver fat content (LFC), both important attributes in the treatment of NASH. The drug combines the reduced caloric intake effects of GLP-1 receptor agonists with the increased energy expenditure and lipometabolic effects of glucagon receptor agonists on the liver

Scott Harris, of Altimmune in the U.S., noted that by Week 12, the 36 subjects receiving Pemvidutide achieved mean weight losses of 4.9%, 10.3%, and 9.0% at the 1.2 mg, 1.8 mg**, and 2.4 mg* doses, respectively, vs. 1.6% for subjects receiving placebo (*p < .01, **p < .005 vs. placebo). Weight loss occurred rapidly and consistently across study weeks. subject plots at 1.8 mg suggested sustained effects over time. MRI-PDFF analyses following 6 weeks of treatment revealed all 5 subjects with fatty liver (≥5%) at baseline, including some as high as 19.5%, receiving 1.8 mg or 2.4 mg Pemvidutide had reductions in LFC to undetectable levels (limit of detection 1.5%), a >90% mean reduction.

Harris concluded that the rapid and potent reductions in body weight and LFC, including double-digit weight loss in 12 weeks and decreases in LFC to levels below the limit of detection, without the need for dose titration, suggest Pemvidutide could be a promising new agent for treatment of NASH and its co-morbidities.

Abstract: Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial (OS124)

Session: Oral Abstract Session, Saturday June 25, 17:30-19:00

Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with Resmetirom

MAESTRO-NAFLD-1 is a 52-week >1200 patient Phase 3 randomized double blind placebo controlled NASH clinical trial to study safety and biomarker effects of Resmetirom, a selective thyroid hormone receptor beta agonist, in 105 NASH patients with F1-F4 fibrosis identified using non-invasive biomarkers and imaging (NCT04197479). A goal of this “real life” NASH study is to identify non-invasive markers that correlate with individual patient response to Resmetirom treatment. The study includes an open label active Resmetirom treatment arm in well-compensated NASH cirrhotic patients.

Stephen Harrison of Pinnacle Research in the U.S., reported that Resmetirom treatment of patients with NASH cirrhosis for up to 52 weeks was safe and effective at lowering markers of CV risk and NASH fibrosis.

Abstract: Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with Resmetirom, a thyroid hormone receptor beta agonist, for 52 weeks (OS121)

Session: Oral Abstract Session, Saturday June 25, 17.30-19:00

A non-calorie restricted low carbohydrate high fat diet improves non–alcoholic fatty liver disease (NAFLD) in people with type 2 diabetes

NAFLD affects 55% of people with type 2 diabetes mellitus (T2DM), and glycaemic control predicts the severity of ballooning and fibrosis in NAFLD. Dietary interventions with low carbohydrates improve glycaemic control but the effect on NAFLD activity is unknown. This

six-month randomised controlled diet trial in 185 people aimed to investigate the effect of a six-month low-carbohydrate high fat (LCHF) diet on NAFLD assessed by ≥2 points improvement in the NAFLD Activity Score (NAS) with at least 1 point improvement in either lobular inflammation or ballooning without worsening of fibrosis and on glycaemic control.

Participants were randomised 2:1 to LCHF or to a diet consisting of high carbohydrates and low fat (HCLF). Both diets were non-calorie-restricted. The LCHF diet consisted of maximum 20 energy percent (E%) carbohydrates, 50-60E% fats and 25-30E% proteins. The HCLF diet consisted of 50-60E% carbohydrates, 20-30E% fats and 20-25E% proteins.

Camilla Dalby Hansen of Odense University Hospital in Denmark noted that liver biopsies were performed and measured HbA1c at baseline and after six months and that participants had ongoing dietitian consultations and compliance was reported continuously through an online food diary platform. Hansen concluded that a six-month non-calorie-restricted LCHF diet improves NAS and HbA1c significantly more than a HCLF diet in people with T2DM as well as bigger weight loss.

Abstract: A non-calorie restricted low carbohydrate high fat diet improves non–alcoholic fatty liver disease (NAFLD) in type 2 diabetes: a six-month randomised controlled trial (GS012)

Session: General Session, Saturday June 25, 13:40-15:40

ENDS

Further information:

Media Registration: Accredited media can apply for free registration here.

Please note: Media representatives must register in order to access the live conference platform that will broadcast the press conferences.

Press Programme: The Official Press Programme and instructions on how to watch the press conferences virtually can be found here:

Embargo Policy: Please note that the ILC 2022 Embargo Policy has changed this edition -media representatives are asked to familiarise themselves with the new policy.

Contact:
(In London)
Michael Kessler
Michael Kessler Media
EASL Media Relations
Email: michael.kessler@intoon-media.com
Mob: +34 655 792 699
Twitter: @mickessler

About EASL’s International Liver Congress™ 
This annual congress is EASL’s flagship event, attracting scientific and medical experts from around the world to learn about the latest in liver research and exchange clinical experience. Attending specialists present, share, debate, and draw conclusions on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is being held entirely digitally due to the global health situation.  

About the  European Association for the Study of the Liver (EASL) 
Since its foundation in 1966, this not-for-profit organisation has grown to over 4,800 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy. 

Thursday June 23, 2022 (London, UK–Results from a Phase III trial have confirmed that the drug Bulevirtide can successfully treat and cure Hepatitis D. The results were presented today at the International Liver Congress 2022 (ILC 2022) in London. Convened by the European Association for the Study of the Liver (EASL), the annual event returns this edition in a hybrid format with some 5000 scientists, doctors, public health officials and patient groups attending in-person at the ExCel London venue this week. Deputy Mayor of London for Business Rajesh Agrawal opened the event yesterday.

A stand-alone cure for Hepatitis D has so far eluded scientists. Found in two to three per cent of people living with Hepatitis B (HBV), Chronic Hepatitis Delta, as it also known, is the most acute of the hepatitis family and extremely hard to treat. With Bulevirtide, an inhibitor of HBV and HDV entry into liver cells, we can for the first time successfully treat Hepatitis D.

Other announcements included Phase III trial results of a new drug to treat acute hepatic porphyria, promising steps towards the long-sought cure for Hepatitis B and results of the largest human trial of preemptive drugs administered before transplantation of a hepatitis C compromised organ that fully protects patients from post operative infection.

“We may well be entering into a new golden age of hepatology science,” said Thomas Berg, Secretary-General of EASL and Head of the Division of Hepatology at Leipzig University Medical Center in Germany. “There is respite coming for those people living with Hepatitis D and we are making progress towards finding a cure for Hepatitis B which affects millions people around the world. The science is inching us towards a potential public health revolution.”

Today’s official press conference highlighted five studies around Hepatitis prevention, treatment and cure selected from over 1,500 abstracts being presented at ILC 2022.

Bulevirtide monotherapy effective and safe for treatment of chronic hepatitis delta

In this study 150 patients with CHD were randomized to 3 treatment groups and stratified based on the absence or presence of compensated cirrhosis: Arm A (control): no active anti-HDV treatment for 48 weeks followed by BLV 10mg/d for 96 weeks (n=51), and Arms B or C: immediate treatment with BLV at 2 mg/d (n=49) or 10 mg/d (n=50), respectively, each for 144 weeks, after which all arms enter treatment-free follow-up for additional 96 weeks. The primary endpoint of combined response was defined as undetectable HDV RNA or decrease by ≥2log₁₀ IU/mL from baseline and ALT normalization at Week 48; other endpoints included viral response (undetectable HDV RNA or decrease by ≥2log₁₀ IU/mL from baseline), ALT normalization, change in HDV RNA levels and change in liver stiffness measured by elastography.

Heiner Wedemeyer of the Medizinische Hochschule in Hannover, Germany reported that at week 48, similar combined responses were seen in the two BLV arms which were significantly greater than in the control arm. Viral and biochemical responses were also similar in the BLV arms and significantly greater than control (p<.0001). BLV was safe and well tolerated during the 48-week treatment period. Asymptomatic elevations in total serum bile salts and injection site reactions occurred at a greater frequency at the higher BLV dose level. There were no participants having an adverse event (AE) leading to discontinuation of BLV and no serious AEs attributed to BLV treatment. Wedemeyer concluded that the study demonstrate that treatment with BLV resulted in a significantly greater combined response compared to control. Monotherapy with BLV was safe and well tolerated.

Abstract: Efficacy and safety of Bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel design study (GS-006) 

Session: General Session, Thursday June 23 13:30-15.00

Efficacy and safety of Givosiran in patients with acute hepatic porphyria (AHP): 36-month results of the phase 3 ENVISION randomised clinical trial

AHP is characterized by acute disabling and sometimes life-threatening neurovisceral attacks that can become recurrent in some patients. ENVISION is a phase 3, randomised, placebo-controlled trial in 93 patients ≥12 years old with AHP who had experienced ≥2 attacks requiring hospitalization, urgent care, or intravenous hemin at home in the past 6M, with a 6M double-blind (DB) period followed by a 30M OLE period.

Manish Thapar of Thomas Jefferson University in Philadelphia, U.S., noted that Givosiran treatment led to sustained lowering of median urinary ALA to near-normal levels and to lowering of PBG levels by >90% in the continuous Givosiran and placebo crossover groups at 36M. Continued Givosiran treatment also led to a sustained reduction in attacks and hemin use in both groups. The proportion of patients with 0 attacks per 3M interval improved over the OLE period, with 86% of patients in the continuous Givosiran group and 92% of patients in the placebo crossover group attack-free at 33-36M. Thapar concluded that Long-term Givosiran treatment provides sustained benefit to patients with AHP, maintaining reduced frequency of attacks and hemin use and further improving physical functioning and quality of life. Most common treatment-related AEs were ISRs, nausea, and fatigue.

Abstract: Efficacy and safety of Givosiran in patients with acute hepatic porphyria: 36-month results of the phase 3 ENVISION randomised clinical trial (OS075)

Session: Oral Abstract Session, Friday June 24, 10:00-11:30

Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study

 This study was designed to both target all hepatitis B virus (HBV) RNAs, thus reducing synthesis of all HBV proteins and also inhibit viral replication by inducing the formation of empty viral particles. The REEF-2 study assessed the efficacy and safety of JNJ-3989 200 mg SC Q4W, JNJ-6379 250 mg PO QD, and nucleos(t)ide analog (NA) PO QD in 130 patients with HBeAg negative CHB.

Kosh Agarwal of King’s College Hospital in the UK noted that no patient in either arm achieved HBsAg seroclearance. Adverse events (AEs) were reported in 81.2% and 71.1% of patients in the active and control arms (grade 3/4 AEs were 15.3% and 4.4%). 7.1% of patients in the active arm had grade 3 eGFR events. After treatment initiation, eGFR reductions were seen in the active arm without further progression on continued treatment. Agarwal concluded that JNJ-3989 + JNJ-6379 + NA showed greater reduction in HBsAg levels over 48 weeks compared to PBO + NA and was generally well tolerated and safe.

Abstract: Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study (GS010)

 Session: General Session, Friday June 24, 13:40- 15.40

 The use of shortened pre-emptive therapy with Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in hepatitis C (HCV) seronegative non-liver solid organ transplant recipients of HCV viremic grafts (OS002)

This study assessed the efficacy and cost effectiveness of preemptive therapy with eight days of a combination of G/P and ezetimibe in 38 recipients of non-liver HCV viremic solid organ transplant (32 kidney tx, 2 kidney/pancreas tx, 3 heart tx, 1 heart/kidney tx). All patients completed treatment. Median age for patients was 60 years and 63% were males. Median time from list for HCV viremic grafts to tx was 32, 52, 71, and 151 days for heart, heart/kidney, kidney, and kidney/pancreas tx recipients respectively. Median donor age was 35 years.

Bashar Aqel of the Mayo Clinic College of Medicine in Phoenix, U.S, reported that combination therapy was continued for 7 days after transplant (total of 8 doses). HCV RNA was monitored up to 24 weeks post-transplant, and patients followed for 1 year to determine graft and patient survivals. All donors had confirmed viremia. All patients achieved undetectable HCV RNA by week 4 post tx and all patients stayed negative 13 weeks post tx (SVR 12 of 100%) (fig 1). The cost of this preemptive approach was significantly lower when compared to the standard of care reactive treatment approach. Treatment was well tolerated, and all patients completed 8 days of combination therapy. Aqel concluded that in the largest multicenter U.S. experience to date, G/P combined with ezetimibe was highly effective in preventing HCV infection in 100% of non-liver solid organ transplant recipients of HCV viremic grafts. Short-term graft and patient survivals are excellent. This approach appears to be cost effective and will potentially eliminate the risk of post-transplant complications from HCV transmission and enhance the use of HCV viremic grafts.

Abstract. Multicenter prospective study for the use of shortened pre-emptive therapy with Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in hepatitis C (HCV) seronegative non-liver solid organ transplant recipients of HCV viremic grafts (OS002)

Session: Oral Abstract Session, Thursday June 23, 16:00-17:30

High Intensity Test and Treat (HITT): an overview of the initiative as part of the Hepatitis C elimination programme in England (OS053)

The NHS is committed to eliminating viral Hepatitis C (HCV) by 2025. Eliminating Hepatitis C in the prison population is key to achieving that goal. The Hepatitis C Trust introduced a ‘High Intensity Test and Treat program’ (HITT) to assess and treat all people in a prison.

Beatrice Emmanouil of the NHS in the UK reported that a team comprising of NHS staff, nurses and peers with lived experience of HCV and incarceration were sent into a prison and offered HCV testing to the whole prison population using prison-wing-based testing with point of care antibody tests, followed-up by using either blood draws or dried blood spot testing for confirmation of viraemia in antibody positive people. All infected people were offered therapy with Direct Acting Antivirals within 2 weeks, and often on the same day using point of care HCV RNA testing and pan-genotypic medication. Between June 2019 and September 2021, 34 HITT initiatives were successfully completed across England: 7 in Female prisons and 27 in Male prisons. Of the 23,388 prison population, 19,049 inmates agreed to be tested. Of those 1,234 people tested positive for presence of HCV antibodies of whom 175 tested positive for presence of HCV RNA. All 175 prisoners found to have a current infection commenced treatment.

Emmanouil concluded that there was great variation between establishments, with remand prisons having significantly higher prevalence than re-settlement prisons. Prevalence was also higher in women’s prisons compared to men’s prisons. The initiative is aiding prisons achieve micro-elimination and has also generated useful data about the prevalence of Hep C in prisons and how it varies between establishments.

Abstract: High Intensity Test and Treat (HITT): an overview of the initiative as part of the Hepatitis C elimination programme in England (OS053)

Session: Oral Abstract Session, Friday June 24, 10:00-11:30

ENDS

Further information:

Media Registration: Accredited media can apply for free registration here.

Please note: Media representatives must register in order to access the live conference platform that will broadcast the press conferences.

Press Programme: The Official Press Programme and instructions on how to watch the press conferences virtually can be found here:

Embargo Policy: Please note that the ILC 2022 Embargo Policy has changed this edition -media representatives are asked to familiarise themselves with the new policy.

Contact:
(In London)
Michael Kessler
Michael Kessler Media
EASL Media Relations
Email: michael.kessler@intoon-media.com
Mob: +34 655 792 699
Twitter: @mickessler

About EASL’s International Liver Congress™ 
This annual congress is EASL’s flagship event, attracting scientific and medical experts from around the world to learn about the latest in liver research and exchange clinical experience. Attending specialists present, share, debate, and draw conclusions on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is being held entirely digitally due to the global health situation.  

About the  European Association for the Study of the Liver (EASL) 
Since its foundation in 1966, this not-for-profit organisation has grown to over 4,800 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy. 

Monday, June 20, 2022 (London, UK) — New breakthroughs in the treatment of Hepatitis D and reducing liver fat will feature prominently in the press programme of the International Liver Congress 2022 (ILC 2022) being held as a hybrid event June 22-26 at the ExCel London. Rajesh Agrawal, the Deputy Mayor of London for Business, will address the opening ceremony on Wednesday June 22.

The congress is convened annually by the European Association for the Study of the Liver (EASL) and this year´s hybrid edition is expected to attract onsite some 6 000 researchers, doctors, policy makers industry leaders and journalists from some 120 countries. The event takes place against the backdrop of an increased prevalence of liver disease across the globe.

Liver disease is now the biggest killer of 35–49-year-olds in the UK. In Europe, chronic liver disease has a substantial impact on young and middle-aged individuals in their prime working years, with the peak age of death occurring in the late 40s and early 50s. This contrasts with mortality from smoking-related and other obesity-related illnesses, such as lung cancer or type 2 diabetes, for which deaths typically occur in the 60s and 70s. Consequently, data from the World Health Organization shows that liver disease is now second only to ischemic heart disease as the leading cause of years of working life lost in Europe. On average, two-thirds of all potential years of life lost due to mortality from liver diseases are years of working life.

A stand-alone cure for Hepatitis D has so far eluded scientists. Found in two to three per cent of people living with Hepatitis B, Chronic Hepatitis Delta, as it also known, is the most acute of the hepatitis family and extremely hard to treat. Results from a Phase III trial of the drug Bulevirtide to treat and cure the disease will be presented in the Official Press Conference: Hepatitis, (hybrid) being held on Thursday June 23. at 11.30 BST.

Immediately following the press conference, Prof. Maria Buti, Chair of the Policy and Public Health Committee at EASL and Dr Philippa Easterbrook Medical Expert, WHO Global HIV, Hepatitis and STI Programme at the World Health Organisation (WHO) will provide media with an in-person update on the acute hepatitis cases affecting children in Europe and beyond.

As a consequence of rising levels of obesity, Non-Alcoholic Fatty Liver Disease (NAFLD) has now become the most common cause of liver disease in Western countries, affecting one in four people and the fastest growing disease in the world. In a proportion of people, NAFLD can cause progressive liver damage, and in some of cases it may even lead to the development of liver cirrhosis and liver cancer. NAFLD currently accounts for one in seven liver transplants in the UK. In the U.S. it is now the most common indication for a liver transplant.

It is estimated that if left unchecked, the annual predicted cost of NAFLD in Europe is estimated to be greater than €35 billion in direct costs to the health system, and a further €200 billion by way of wider costs to society.

The search for new treatments for NAFLD has gained momentum over the past few years and the results of some key drug trials will be presented in the 2nd Official Press Conference: NAFLD, (hybrid) taking place on Friday June 24 at 11:30. The first human trial of a new drug Pemvidutide with the potential to reduce both weight and liver fat will report its results.

Results will also be released from a randomised controlled trial on a low carbohydrate/high fat diet and its potential to impact on fatty liver.

ENDS

Further information

Media Registration: Accredited media can apply for free registration here.

Please note: Media representatives must register in order to access the live conference platform that will broadcast the press conferences.

Press Programme: The Official Press Programme and instructions on how to watch the press conferences virtually can be found here:

Embargo Policy: Please note that the ILC2022 Embargo Policy has changed this edition -media representatives are asked to familiarise themselves with the new policy.

Further Information:

(In London)

Michael Kessler
Michael Kessler Media
EASL Media Relations
Email: michael.kessler@intoon-media.com
Mob: +34 655 792 699
Twitter: @mickessler

For any 1:1 interviews with Dr Philippa Easterbrook please contact Rayyan Sabet-Parry, Communication Officer at WHO.
Email: rsabetparry@who.int

About The International Liver Congress™

This annual congress is EASL’s flagship event, attracting scientific and medical experts from around the world to learn about the latest in liver research and exchange clinical experience. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is being held entirely digitally due to the global health situation.

About The European Association for the Study of the Liver (EASL)

Since its foundation in 1966, this not-for-profit organisation has grown to over 4,500 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy.

Wednesday 1 June 2022 (Geneva, Switzerland) — New breakthroughs in the treatment of Hepatitis D and reducing liver fat will feature prominently in the press programme of the (ILC 2022) being held as a hybrid event June 22-26 at the ExCel London.

The congress is convened annually by the European Association for the Study of the Liver (EASL) and this year´s edition is expected to attract onsite some 6 000 researchers, doctors, policy makers industry leaders and journalists from some 120 countries. The event takes place against the backdrop of an increased prevalence of liver disease across the globe.

In Europe, chronic liver disease has a substantial impact on young and middle-aged individuals in their prime working years, with the peak age of death occurring in the late 40s and early 50s. This contrasts with mortality from smoking-related and other obesity-related illnesses, such as lung cancer or type 2 diabetes, for which deaths typically occur in the 60s and 70s. Consequently, data from the World Health Organization shows that liver disease is now second only to ischemic heart disease as the leading cause of years of working life lost in Europe. On average, two-thirds of all potential years of life lost due to mortality from liver diseases are years of working life. Liver disease is now the biggest killer of 35–49-year-olds in the UK.

A stand-alone cure for Hepatitis D has so far eluded scientists. Found in two to three per cent of people living with Hepatitis B, Chronic Hepatitis Delta, as it also known, is the most acute of the hepatitis family and extremely hard to treat. Results from a Phase III trial of the drug Bulevirtide to treat the disease will be presented in the Official Press Conference: Hepatitis, (hybrid) being held on Thursday June 23.

In the same press conference Maria Buti, Head of Public Health at EASL, will also provide an update on the acute hepatitis cases affecting children in Europe and beyond.

As a consequence of rising levels of obesity, NAFLD has now become the most common cause of liver disease in Western countries, affecting one in four people. In a proportion of people, NAFLD can cause progressive liver damage, and in some of cases it may even lead to the development of liver cirrhosis and liver cancer. NAFLD currently accounts for one in seven liver transplants in the UK. In the U.S. it is now the most common indication for a liver transplant. More generally, liver disease is now the most common cause of premature mortality in the UK.

The COVID-19 pandemic has also slowed down both the rates of liver transplants and donor organ numbers. Results from a Phase III study of a pre-emptive therapy for patients that would enable them to safely receive a compromised Hepatitis C liver transplant, are eagerly awaited.

The search for new treatments for NAFLD has gained momentum over the past few years and the results of some key drug trials will be presented in the 2nd Official Press Conference: NAFLD,(hybrid) taking place on Friday June 24. Results will also be released from a randomised controlled trial on a low carbohydrate/high fat diet and its impact on Non-Alcoholic Fatty Liver Disease (NAFLD), the world´s fastest growing disease.

“NAFLD is already a public health crisis in the west, and we urgently need new therapeutics to reduce its burden,” said Thomas Berg, Secretary-General of EASL and Head of the Division of Hepatology at Leipzig University Medical Center in Germany.

“If left unchecked, the annual predicted cost of NAFLD in Europe is estimated to be greater than €35 billion in direct costs to the health system, and a further €200 billion by way of wider costs to society.”

 ENDS 

Further information 

Media Registration: Accredited media can apply for free registration here 

Programme: For updates to the congress programme see here 

Press Programme: All ILC 2022 Official Press Conferences held onsite will also be broadcast live on Zoom for registered media. 

Embargo Policy: Media representatives are asked to familiarise themselves with the official policy ILC 2022 Embargo Policy 

Further Information:  

Michael Kessler 
Michael Kessler Media
EASL Media Relations
Email: michael.kessler@intoon-media.com
Mob: +34 655 792 699
Twitter: @mickessler 

About EASL’s International Liver Congress™ 
This annual congress is EASL’s flagship event, attracting scientific and medical experts from around the world to learn about the latest in liver research and exchange clinical experience. Attending specialists present, share, debate, and draw conclusions on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is being held entirely digitally due to the global health situation.  

About the  European Association for the Study of the Liver (EASL) 
Since its foundation in 1966, this not-for-profit organisation has grown to over 4,800 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy. 

Thursday, April 14, 2022 (Geneva, Switzerland) —The latest and 57th iteration of International Liver Congress™ (ILC 2022) returns as an in-person event in London this coming June (22–26). The event is being held at the ExCeL London exhibition centre. 

The congress is convened annually by the European Association for the Study of the Liver (EASL) and is expected to attract some 8,000 researchers, doctors, policymakers, and industry leaders working on liver disease from some 120 countries. The past two iterations of the conference have been held virtually due to the COVID-19 pandemic. For registered delegates unable to attend the in-person event, all sessions will be available digitally. All official onsite press conferences will be broadcast live via Zoom. 

“We are facing sobering times in Europe now and we express our solidarity to those affected by the conflict in Ukraine,” said Prof. Thomas Berg, Secretary General of EASL and Head of the Division of Hepatology at Leipzig University Medical Center in Germany. 

“EASL remains committed to promoting research, sharing, and communication among professionals, across the region and beyond, interested in the liver and its disorders. EASL is delighted that ILC 2022 is both returning to an in-person format and being held in London, a city rich in hepatology science and practice.” 

The well-documented and disproportionate impact of COVID-19 on people living with noncommunicable diseases such as diabetes, obesity, and hypertension also has researchers worried about the vulnerability of people living with non-alcohol related fatty liver disease (NAFLD) to the novel coronavirus. The need to find effective tools to measure this disease and new drugs to treat it is more urgent than ever. 

As a consequence of rising levels of obesity, NAFLD has now become the most common cause of liver disease in Western countries, affecting one in four people. 

Liver disease is on the rise and the fastest growing cause of death in the UK compared to other major killer diseases, such as heart disease and cancer, in which the number of deaths have either remained stable or decreased. It is the biggest cause of death in people aged 35 to 49. 

NAFLD is already the fastest growing cause of hepatocellular carcinoma (HCC), the commonest form of liver cancer in the USA, France, and the UK. Non-alcohol related steatohepatitis (NASH) is the second, more serious stage of NAFLD. 

If left unchecked, the annual predicted cost of NAFLD in Europe is estimated to be greater than EUR 35 billion in direct costs to the health system, and a further EUR 200 billion by way of wider costs to society. 

 

ENDS 

Further information 

Media Registration: Accredited media can apply for free registration here 

Programme: For updates to the congress programme see here 

Press Programme: All ILC 2022 Official Press Conferences held onsite will also be broadcast live on Zoom for registered media. 

Embargo Policy: Media representatives are asked to familiarise themselves with the official policy ILC 2022 Embargo Policy 

Further Information:  

Michael Kessler  

Michael Kessler Media  

EASL Media Relations 

Email: michael.kessler@intoon-media.com 

Mob: +34 655 792 699 

Twitter: @mickessler 

About EASL’s International Liver Congress™ 
This annual congress is EASL’s flagship event, attracting scientific and medical experts from around the world to learn about the latest in liver research and exchange clinical experience. Attending specialists present, share, debate, and draw conclusions on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is being held entirely digitally due to the global health situation.  

About the  European Association for the Study of the Liver (EASL) 
Since its foundation in 1966, this not-for-profit organisation has grown to over 4,800 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy.